Stock Rating Downgrade Reflecting eroding fundamentals and low Appreciation Potential, the Value Trend Rating for Piper Sandler Cos (NYSE: PIPR) weakened during the last several trading days. PIPR’s current Value Trend Rating is C and […]
Stock Rating Downgrade The Value Trend Rating for OncoGenex Pharmaceuticals Inc (NASDAQ: VRSK) weakened of late from B to C reflecting eroding fundamentals and low Appreciation Potential. Details supporting this lower rating are included in […]
Stock Rating Upgrade Of late the Value Trend Rating for Nucor Corp (NYSE: NUE) improved from D to C reflecting improving fundamentals and high Appreciation Potential. Recent Price Action On 3/7/25, Nucor Corp (NYSE: NUE) […]
Stock Rating Upgrade The Value Trend Rating for NewtekOne Inc (NASDAQ: NEWT) rose significantly recently from C to A reflecting improving fundamentals and high Appreciation Potential. Details supporting this higher rating are included in our […]
On 3/7/25, National CineMedia Inc (NASDAQ: NCMI) stock suffered a major decline of -17.8%, closing at $5.22. Moreover, this decline was accompanied by exceptionally high trading volume at 517% of normal. Relative to the market […]
Stock Rating Upgrade In the last week the Value Trend Rating for NOW Inc (NYSE: DNOW) rose significantly from C to A reflecting improving fundamentals and high Appreciation Potential. Recent Price Action NOW Inc (NYSE: […]
MiMedx Group Inc (NASDAQ: MDXG) suffers from significant negative changes in fundamentals: the consensus estimate for December, 2025 decreased significantly, significant quarterly earnings deceleration occurred, and the consensus estimate for December, 2026 decreased significantly. MiMedx […]
Stock Rating Upgrade The Value Trend Rating for L.B. Foster Co (NASDAQ: FSTR) improved of late from C to B reflecting improving fundamentals and high Appreciation Potential. Details supporting this higher rating are included in […]
Karyopharm Therapeutics Inc (NASDAQ: KPTI) stock closed at $6.89 on 3/7/25 after a major increase of 10.8%. Moreover, this advance was accompanied by unusually high trading volume at 178% of normal. The stock has declined […]
Stock Rating Upgrade Reflecting improving fundamentals and high Appreciation Potential, the Value Trend Rating for Iovance Biotherapeutics Inc (NASDAQ: IOVA) rose significantly in recent days. IOVA’s current Value Trend Rating is C and the prior […]
Privacy Statement Terms Of Use ©2024 PriceTarget Research